AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by…